🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Si-Bone CFO sells over $42k in company stock

Published 05/07/2024, 22:46
SIBN
-

Anshul Maheshwari, the Chief Financial Officer of SI-BONE, Inc. (NASDAQ:SIBN), has recently sold a total of $42,693 worth of company stock, according to the latest SEC filings. The transactions, which took place on July 2, 2024, involved the sale of company shares at prices ranging from $12.8973 to $12.9067.

The sales were executed in multiple trades, with part of the shares being sold at a weighted average price of $12.8973 and the remainder at a weighted average of $12.9067. The exact number of shares sold at each price point within these ranges can be provided upon request, as noted in the footnotes of the SEC filing.

These stock sales by the CFO were not discretionary trades but were conducted to cover tax withholding obligations related to the vesting of restricted stock units, as indicated in the filing's footnotes. It is a common practice for executives to sell shares in order to satisfy tax liabilities triggered by the vesting of equity awards.

Following these transactions, Maheshwari still holds a significant number of SI-BONE shares, with the SEC filing indicating a post-transaction total of 201,180 shares, including 138,180 shares issuable upon the settlement of restricted stock units.

Investors and followers of SI-BONE, a company specializing in surgical and medical instruments and apparatus, often monitor the buying and selling activity of its top executives for insights into their perspective on the company's financial health and future prospects. However, it's important to note that such transactions don't always provide a complete picture and can be influenced by various personal financial considerations.

In other recent news, SI-BONE, Inc., a medical device company, has seen several significant developments. The company reported a 16% increase in worldwide revenue to $37.9 million for the first quarter of 2024, following the successful launch of the iFuse Bedrock Granite implant. SI-BONE has also raised its revenue guidance for 2024, indicating anticipated growth across its markets.

In addition, the company has amended its charter to limit the liability of certain officers, a move approved by stockholders during the 2024 Annual Meeting. This amendment aligns with recent changes to the Delaware General Corporation Law and could potentially shield these officers from personal financial risk related to their corporate decision-making.

However, BofA Securities has revised down its earnings per share estimates for SI-BONE for the calendar years 2024, 2025, and 2026, maintaining an Underperform rating for the company. The firm also reduced its price target for SI-BONE shares from $26 to $21 due to concerns over the company's sales forecast. These are among the recent developments related to SI-BONE.

InvestingPro Insights

As SI-BONE, Inc. (NASDAQ:SIBN) navigates the market, recent data from InvestingPro provides a snapshot of the company's financial health and market performance. With a market capitalization of $536.07 million, SI-BONE's financial position shows a blend of strengths and challenges.

One of the key InvestingPro Tips for SI-BONE is that the company holds more cash than debt on its balance sheet, which is a positive indicator of financial stability. This can reassure investors about the company's ability to manage its financial obligations and invest in growth opportunities.

However, SI-BONE has not been profitable over the last twelve months, as indicated by a negative P/E ratio of -11.97, adjusted to -12.41 for the last twelve months as of Q1 2024. This aligns with the analysts' outlook, as they do not anticipate the company will be profitable this year. Additionally, six analysts have revised their earnings estimates downwards for the upcoming period, suggesting potential concerns about the company's future earnings capacity.

Despite these challenges, SI-BONE's liquid assets exceed its short-term obligations, which is another InvestingPro Tip that highlights the company's liquidity and short-term financial health. This is a critical factor for investors assessing the risk of investing in the company.

For those interested in a deeper analysis, there are more InvestingPro Tips available for SI-BONE at https://www.investing.com/pro/SIBN. By using the coupon code PRONEWS24, readers can get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking access to valuable insights that can inform investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.